Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eptinezumab - Lundbeck Seattle BioPharmaceuticals

Next Previous
Search
Drug Profile

Eptinezumab - Lundbeck Seattle BioPharmaceuticals

Alternative Names: ALD-403; Eptinezumab-jjmr; Lu-AG09221; VYEPTI

Latest Information Update: 16 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alder Biopharmaceuticals
  • Developer Lundbeck A/S; Lundbeck Seattle BioPharmaceuticals Inc.
  • Class Analgesics; Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Phase III Cluster headache

Most Recent Events

  • 04 Apr 2025 Efficcay data from the phase III PREVAIL trial in Migraine released by Lundbeck A/S
  • 17 Feb 2025 Lundbeck A/S completes the Phase-III Sunrise trial in Migraine (Prevention) in South Korea, China, Georgia, Japan, Poland, Slovakia, Spain, Taiwan (IV, Infusion) (NCT04921384)
  • 08 Jun 2024 Lundbeck completes phase III trial for Migraine (Prevention, In adults, In the elderly) in Japan (IV, Infusion) (NCT05064371)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top